DF6000 / Dragonfly Therap - LARVOL DELTA

Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET Immunotherapy Drug Candidate (PRNewswire) - "Dragonfly to receive a $12 million payment and is eligible to receive potential future milestones and royalties on net sales…Dragonfly Therapeutics, Inc…announced that Bristol Myers Squibb ('BMS') has licensed its fourth TriNKET™ immunotherapy drug candidate from Dragonfly. Since the original 2017 collaboration focusing on hematology malignancies, the companies have agreed two additional collaborations across solid tumors, and autoimmune disease."

Licensing / partnership • Oncology